z-logo
Premium
Chronic opioid use after laryngeal cancer treatment
Author(s) -
Starr Nicole,
Oyler Douglas R.,
Schadler Aric,
Aouad Rony K.
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26591
Subject(s) - medicine , opioid , chronic pain , morphine , retrospective cohort study , medical prescription , lung cancer , cancer , anesthesia , physical therapy , pharmacology , receptor
Background Survivors of head and neck cancer may be at increased risk for chronic opioid use and questions remain about risk factors. Methods Retrospective study of patients with laryngeal cancer prescribed opioids utilizing the Truven Health Marketscan database. Patients had laryngeal cancer, underwent treatment, filled an opioid prescription, and were enrolled in this private insurance plan 1 year prior to and after treatment. Results In this study, 7484 patients were included; 17.2% developed chronic opioid use, defined as consecutive opioid fills at least 90 days after treatment cessation. Early opioid use (OR = 3.607, 95% CI [3.125–4.163]), tobacco use (OR = 1.28, 95% CI [1.117–1.467]), median morphine milligram equivalent (MME; OR = 1.001, 95% CI [1.000–1.0001]), and radiation alone (OR = 1.435, 95% CI [1.199–1.717]) were predictive of chronic opioid use. Conclusions Nearly one in five patients prescribed opioids during treatment developed chronic use. Providers should discuss the risk of chronic opioid use, set expectations for opioid weaning, and consider adjunct pain regimens to develop effective pain management strategies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here